| Date | Title | | | December 23, 2015 | OncoCyte Appoints Dr. Andrew J. Last to Its Board of Directors| Dr. Last Brings Over 30 Years of Corporate Strategy Experience to
Liquid Biopsy Diagnostics Company
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 23, 2015--
OncoCyte Corporation (“OncoCyte”), a company focused on non-invasive
cancer diagnostics, announced the appointment of Dr. Andrew J. Last as
an independent member of OncoCyte’s Board of Directors. Dr. Last is
currently the Executive Vice President & Chief Operating Officer at
Affymet... |
|  | | December 03, 2015 | LifeMap Solutions Launches COPD Navigator App for Consumers and Commercial Partners| LifeMap’s first enterprise customer SuperCare Health to deploy
customized COPD Navigator app with enhanced features, SuperCare
iBreathe, to patients
SAN JOSE, Calif.--(BUSINESS WIRE)--Dec. 3, 2015--
LifeMap Solutions, a digital-health subsidiary of BioTime, Inc. (NYSE
MKT and TASE: BTX) known for its ResearchKit-enabled app Asthma Health,
today announced that its HealthKit-compliant iOS app, COPD
Navigator, is now available for free download f... |
| | | December 02, 2015 | LifeMap Sciences Partners with MedGenome to Enrich NGS Analysis Reporting with Oncology Data| Agreement strengthens LifeMap Sciences position in the NGS oncology market and provides LifeMap users with the option to access annotated cancer variants, as well as approved drugs and clinical trials related to a subject’s sequence information.
ALAMEDA, Calif. & SAN FRANCISCO & BANGALORE, India--December 2, 2015-- LifeMap Sciences, Inc. (“LifeMap”), a life sciences technology company and a subsidiary of BioTime, Inc., and MedGenome, Inc. (“MedGenome”), a genomics-based diagnos... |
| | | November 24, 2015 | LifeMap Solutions Appoints Robert W. Peabody Chief Financial Officer| SAN JOSE, Calif.--(BUSINESS WIRE)--Nov. 24, 2015--LifeMap Solutions, a subsidiary of BioTime, Inc., today announced the appointment of Robert W. Peabody as Chief Financial Officer. LifeMap is a technology pioneer, and an emerging provider of digital mobile health products, including ResearchKit and HealthKit apps, in collaboration with the Icahn School of Medicine at Mount Sinai. Mr. Peabody brings over 30 years of early stage company experience to LifeMap Solutions.
“Bob’... |
| | | November 09, 2015 | Asterias Biotherapeutics Reports Third Quarter Results| Conference Call and Webcast Today, November 9, at 4:30 p.m. ET
MENLO PARK, Calif., Nov. 9, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today reported financial and operating results for the third quarter ended September 30, 2015.
"Asterias continued to achieve solid progress in the third quarter toward advancing the clinical development of our key therapeutic programs," stated Pedro Lic... |
| | | November 06, 2015 | /C O R R E C T I O N -- Asterias Biotherapeutics, Inc./| In the news release, Asterias Biotherapeutics to Report Third Quarter Results on November 9, 2015, issued 05-Nov-2015 by Asterias Biotherapeutics, Inc. over PR Newswire, we are advised by the company that the webcast phone numbers and passcodes were incorrect, as originally issued inadvertently. The complete, corrected release follows:
Asterias Biotherapeutics to Report Third Quarter Results on November 9, 2015
MENLO PARK, Calif., Nov. 5, 2015 /PRNewswire/ -- Asterias Biotherapeutics, In... |
| | | November 05, 2015 | Asterias Biotherapeutics to Report Third Quarter Results on November 9, 2015| MENLO PARK, Calif., Nov. 5, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that it will release third quarter financial and operating results on Monday, November 9, 2015 after the close of the U.S. financial markets. The Company will host a conference call and webcast on Monday, November 9, 2015 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the results and corporate develop... |
| | | November 04, 2015 | LifeMap Sciences, a Subsidiary of BioTime, and Lab7 Systems Announce Partnership and Launch of Integrated NGS Analysis Solution | LifeMap’s VarElect, The NGS Phenotyper, is now integrated into Lab7 ESP DNA sequence analysis, outputs and reports
Lab7 ESP users can leverage VarElect’s integrated features to rapidly identify causal mutations and examine related biological evidence
ALAMEDA, Calif. & AUSTIN, Tex., November 4, 2015 – LifeMap Sciences, Inc. (“LifeMap”), a subsidiary of BioTime, Inc., and Lab7 Systems, Inc., announced today a partnership and launch of an integrated solution in the next-generatio... |
| | | November 02, 2015 | Georgia Erbez Appointed Chief Financial Officer Of Asterias Biotherapeutics| Executive Brings Proven Executive Leadership and Financial Acumen to Asterias
MENLO PARK, Calif., Nov. 2, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced the appointment of Georgia Erbez to the position of Chief Financial Officer of the Company effective November 9, 2015. Ms. Erbez joins Asterias after serving as a financial consultant to numerous biotechnology companies and p... |
| | | October 20, 2015 | Asterias Biotherapeutics to Begin Dose Escalation in the SCiStar Phase 1/2a Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury| No Serious Adverse Events Reported with Initial AST-OPC1 Dose
First Patient in Initial Dose Cohort Shows Neurological Improvement
MENLO PARK, Calif., Oct. 20, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that its Data Monitoring Committee has reviewed the initial safety data from all three patients in the first cohort and has recommended dose escalation to the second coho... |
| | | October 13, 2015 | Asterias Biotherapeutics Announces Collaboration with Cell Therapy Catapult to Scale Production of AST-VAC2| MENLO PARK, Calif., Oct. 13, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), has signed an agreement with the UK-based Cell Therapy Catapult to advance development of large scale manufacturing processes for AST-VAC2, Asterias' allogeneic dendritic cell immunotherapy. Under the agreement, the Cell Therapy Catapult will streamline and scale manufacturing processes for AST-VAC2 to support advanced clinical trials and eventual commercialization of AST-VAC2.
The Cell Therapy C... |
| | | October 12, 2015 | Asterias Biotherapeutics to Participate in Webcast on Innovations in Regenerative Medicine & Curative Biologics| MENLO PARK, Calif., Oct. 12, 2015 /PRNewswire/ -- Jane S. Lebkowski, Ph.D., President of R&D and Chief Scientific Officer of Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, will participate in a BioPharma Dealmakers webcast, sponsored in part by Asterias Biotherapeutics, featuring four companies developing regenerative medicine. Dr. Lebkowski will discuss the progress to date for the Company's transformative tech... |
| | | October 08, 2015 | LifeMap Sciences’ NGS Analysis and Interpretation Tools VarElect and GeneAnalytics™ Licensed by SciLifeLab| ALAMEDA, Calif., October 8, 2015 – LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today that its next generation sequencing (“NGS”) analysis and interpretation tools, VarElect (http://varelect.genecards.org), the NGS phenotyper, and GeneAnalytics™ (http://geneanalytics.genecards.org/), a novel gene set analysis tool, has been licensed by SciLifeLab (www.scilifelab.se). SciLifeLab is a Sweden-based leading provider of molecular biosciences services to leading biome... |
| | | October 05, 2015 | Asterias Biotherapeutics to Present at 2015 Stem Cell Meeting on the Mesa| MENLO PARK, Calif., Oct. 5, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Jane Lebkowski, Ph.D., President Research and Development and Chief Scientific Officer, will present at the annual Partnering Forum, part of the Stem Cell Meeting on the Mesa on October 7, 2015, at 2:15 PM ET/11:15 AM PT. Dr. Lebkowski will discuss the progress to date for the Company's transformativ... |
| | | September 30, 2015 | Heraeus Medical GmbH and BioTime Subsidiary OrthoCyte Corporation Enter Into Exclusive Worldwide Development and Licensing Agreements| Agreements Provide for the Development of an Innovative Cell
Therapy Product for Bone Grafting in Orthopedic Unmet Needs
Heraeus Medical to Fund All Product Development and Commercial
Sales and Marketing Efforts
OrthoCyte Will Be Responsible for Product Development and
Manufacturing
HANAU, Germany & ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 30, 2015--
Heraeus Medical GmbH, one of the leading c... |
| | | September 29, 2015 | Mount Sinai and LifeMap Solutions Announce Initial Results for Asthma Health App and New Features to Enhance Clinical Impact| NEW YORK--(BUSINESS WIRE)--Sep. 29, 2015--
The Icahn School of Medicine at Mount Sinai and LifeMap Solutions, a
digital-health subsidiary of BioTime, Inc., today announced initial
results and new clinical features for their free Asthma
Health app. Released six months ago, the app enables individuals
with asthma to participate in a large-scale medical research study by
simply using their Apple iPhones. The app’s newest features—the “Doctor
Dashboar... |
| | | September 14, 2015 | BioTime Subsidiary OncoCyte Corporation Appoints Cavan Redmond to its Board of Directors| Former CEO of WebMD and Group President of Pfizer Brings Over 25
Years of Corporate Strategy Experience to Liquid Biopsy Diagnostics
Company
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 14, 2015--
BioTime, Inc. (NYSE MKT and TASE: BTX) announced the appointment of
Cavan Redmond as an independent member of the Board of Directors of
BioTime’s subsidiary OncoCyte Corporation. Mr. Redmond, 54, is a
seasoned healthcare strategist who has held a number of... |
| | | September 09, 2015 | Asterias Biotherapeutics Announces Publication of Preclinical Data that Supports the Safety and Use of AST-OPC1 as a Treatment for Spinal Cord Injury (SCI)| MENLO PARK, Calif., Sept. 9, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced the publication of a manuscript in Regenerative Medicine relating to AST-OPC1 (oligodendrocyte progenitor cells). The publication describes the results from preclinical safety studies that were submitted to the U.S. Food and Drug Administration (FDA) as part of an Investigational New Drug Application. AST... |
| | | August 31, 2015 | BioTime Subsidiary Asterias Therapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury| Safety of the Injection Procedure Confirmed with No Reported Serious
Adverse Events
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 31, 2015--
BioTime, Inc. (NYSE MKT: BTX) announced today that subsidiary Asterias
Biotherapeutics, Inc., a biotechnology company focused on the emerging
field of regenerative medicine, reported that the third patient was
successfully dosed at Chicago-based Rush University Medical Center in a
Phase 1/2a clinical t... |
| | | August 31, 2015 | Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury| Safety of the Injection Procedure Confirmed with No Reported Serious Adverse Events
MENLO PARK, Calif., Aug. 31, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that the third patient was successfully dosed at Chicago-based Rush University Medical Center in a Phase 1/2a clinical trial evaluating activity of escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) in newl... |
| | | August 27, 2015 | Asterias Biotherapeutics to Present at Upcoming Investor Conferences| MENLO PARK, Calif., Aug. 27, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that executives from the company will present at two investor conferences in the month of September.
Pedro Lichtinger, Chief Executive Officer, will present at Rodman & Renshaw's 17th Annual Global Investment Conference on Thursday, September 10, 2015 at 10:25am ET/7:25am PT at the St. Regis Ho... |
| | | August 18, 2015 | The Wistar Institute and BioTime Subsidiary OncoCyte Corporation Expand Agreement to Develop Molecular Diagnostic Test for the Detection of Lung Cancer| Agreement provides for continued development of a liquid biopsy test
designed to aid physicians in the early, non-invasive detection of lung
cancer
PHILADELPHIA & ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 18, 2015--
The Wistar Institute and BioTime, Inc. (NYSE MKT: BTX) announced that
Wistar and BioTime’s subsidiary OncoCyte Corporation, have expanded
their collaborative relationship to develop a simple, non-invasive,
blood-based test designe... |
| | | August 10, 2015 | Asterias Biotherapeutics Reports Second Quarter Results| Conference Call and Webcast Today, August 10, at 4:30 p.m. ET
MENLO PARK, Calif., Aug. 10, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today reported financial and operating results for the second quarter ended June 30, 2015.
"In the second quarter, we continued to make progress on multiple fronts toward advancing the clinical development of our key therapeutic programs," stated Pedro L... |
| | | July 29, 2015 | Asterias Biotherapeutics to Report Second Quarter Results on August 10, 2015| MENLO PARK, Calif., July 29, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that it will release second quarter financial and operating results on Monday, August 10, 2015 after the close of the U.S. financial markets. The Company will host a conference call and webcast on Monday, August 10, 2015 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the results and corporate develop... |
| | | July 15, 2015 | OncoCyte Announces Appointment of Andy Arno to Board of Directors| -- Appointment Brings 30 Years of Strategic Advisory and
Capital Markets Experience
-- OncoCyte is Advancing Three Non-invasive Cancer Diagnostics
Through Clinical Trials
ALAMEDA, Calif.--(BUSINESS WIRE)--Jul. 15, 2015--
OncoCyte Corporation, a cancer diagnostics company and a member of the
BioTime, Inc. (NYSE MKT:BTX) family of companies, announced today that
Andy Arno has been appointed to the Company’s Board of Directors.
... |
| | | July 15, 2015 | LifeMap Sciences Announces the Next Generation of GeneCards - Version 4.0| The New GeneCards® Powers LifeMap’s NGS Analysis and Interpretation Platform
Enables Rapid Integration with Partners in the NGS Storage, Analysis and Interpretation Markets and Will Allow for Partnering Opportunities
New User Interface, Functionality and Application Programming Interface (“API”) API Provide Improved Offering for Academia, Biopharma and Diagnostic Companies
ALAMEDA, Calif., July 15, 2015 – LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today ... |
| | | June 30, 2015 | Asterias Biotherapeutics Added To Russell 2000®, Russell 3000®, Russell Global and Russell Microcap® Indexes| MENLO PARK, Calif., June 30, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that it has been added to the Russell 2000®, Russell 3000®, Russell Global and Russell Microcap® indexes following Russell Investments' ("Russell") reconstitution of its comprehensive set of U.S. and global equity indexes after the close of the U.S. markets on June 26, 2015. Each June, Russell completely ... |
| | | June 16, 2015 | William Annett Named Chief Executive Officer of OncoCyte Corporation| -- Appointment Brings Commercial, Operational, and Financial
Expertise from Several Companies, Including Genentech and Accenture
-- Biotechnology and Diagnostics Industry Leader to Focus on Later
Stages of Clinical Trials and Commercialization of Three Non-Invasive
Cancer Diagnostic Products
-- All Clinical Trials Progressing to Later Stages; Interim
Bladder Cancer Diagnostic Clinical Results Announced Earlier This Year
in Collabor... |
| | | June 15, 2015 | Preliminary Reconstitutions of Russell 3000®, Russell Global and Russell Microcap® Indexes Include Asterias Biotherapeutics| Final Determination of Index Inclusion to be Published on June 26th
MENLO PARK, Calif., June 15, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine is included in the preliminary list of additions to three Russell Investments ("Russell") indexes. According to information published by Russell, Asterias is expected to be added to the Russell 3000®, Russell Global and Russell Microcap® indexes when ... |
| | | June 08, 2015 | Asterias Biotherapeutics Announces First Patient Treated in Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury| MENLO PARK, Calif., June 8, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that the first patient was successfully dosed at the Atlanta-based Shepherd Center in a Phase 1/2a clinical trial evaluating activity of escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI). The Phase 1/2... |
| | | June 01, 2015 | Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML)| Data Presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
Management to Host Conference Call and Webcast to Discuss AST-VAC1 Development Strategy on Wednesday, June 3, 2015, at 4:30 p.m. ET
MENLO PARK, Calif., June 1, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced positive, new, long-term follow-up data from a Phase 2 clinical trial of AST-VAC1 ... |
| | | May 26, 2015 | Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants| MENLO PARK, Calif., May 26, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that all outstanding common share purchase warrants originally issued in June 2014 were exercised prior to their expiry on June 15, 2015, resulting in total proceeds to the Company of $11.7 million.
"We thank our shareholders for their continued support," said Pedro Lichtinger, President and CEO of Aste... |
| | | May 19, 2015 | OncoCyte’s Collaborators at The Wistar Institute Present Positive Clinical Interim Results of Blood-Based Diagnostic Test for Non-Invasive Detection of Lung Cancer| Data Presented at the 2015 American Thoracic Society International
Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--May 19, 2015--
BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation
today announced the presentation of positive interim clinical results
demonstrating the high level of observed sensitivity and specificity in
the assayed samples of a simple blood-based test designed to aid
physicians in the early detection of lung ca... |
| | | May 14, 2015 | OncoCyte Corporation Completes Equity Financing Round| - Capital to fund further development and
commercialization efforts of cancer diagnostic tests by BioTime
subsidiary -
ALAMEDA, Calif.--(BUSINESS WIRE)--May 14, 2015--
BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation
today announced that OncoCyte has received a new round of financing to
fund further development and commercialization activities for its cancer
diagnostic products. With completion of the financing, which inclu... |
| | | May 14, 2015 | Asterias Biotherapeutics Announces Availability of Abstract with Phase 2 Clinical Data on Cancer Vaccine AST-VAC1 in Acute Myelogenous Leukemia (AML)| Data to be Featured in Oral Presentation at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
MENLO PARK, Calif., May 14, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced the online availability of an abstract reporting data on long-term follow-up of patients with acute myelogenous leukemia (AML) from the Phase 2 clinical trial of the Company's autologous telo... |
| | | May 07, 2015 | Asterias Biotherapeutics Promotes Edward Wirth, M.D., Ph.D. to Chief Medical Officer| MENLO PARK, Calif., May 7, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced the promotion of Edward D. Wirth, III, M.D., Ph.D., to the newly created role of Chief Medical Officer. Dr. Wirth was Chief Translational Officer since joining Asterias in March 2013.
In his new role, Dr. Wirth will become an executive officer of the Company and provide strategic leadership for Asterias... |
| | | May 07, 2015 | Asterias Biotherapeutics Reports First Quarter Results| Conference Call and Webcast Today, May 7, at 4:30 p.m. ET
Asterias to Host Investor Meeting Tomorrow, May 8, to Review AST-OPC1 Clinical Development Strategy for Spinal Cord Injury
MENLO PARK, Calif., May 7, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today reported financial and operating results for the first quarter ended March 31, 2015.
"Asterias remains focused on our two potent... |
| | | May 06, 2015 | Asterias Biotherapeutics to Host Investor Meeting to Review Clinical Development Strategy for AST-OPC1 in Spinal Cord Injury| Dr. John Steeves, Co-Chair of Spinal Cord Outcomes Partnership Endeavor, to Discuss Clinical Foundations for Endpoints and Outcome Measures in Spinal Cord Injury Trials
Webcast Scheduled at 9:30 a.m. ET on May 8, 2015
MENLO PARK, Calif., May 6, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that the Company will host a meeting with the investment community to review the cli... |
| | | April 30, 2015 | Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015| MENLO PARK, Calif., April 30, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that it will release first quarter financial and operating results on Thursday, May 7, 2015 after the close of the U.S. financial markets. The Company will host a conference call and webcast on Thursday, May 7, 2015 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the results and recent corporate deve... |
| | | April 21, 2015 | Asterias Biotherapeutics Announces Phase 2 Clinical Data on Autologous Telomerase-based Dendritic Cell Cancer Vaccine AST-VAC1 Selected for Oral Presentation at the 2015 ASCO Annual Meeting| MENLO PARK, Calif., April 21, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that the abstract describing long-term follow-up of patients with acute myelogenous leukemia (AML) from the Phase 2 clinical trial of the Company's autologous telomerase-based dendritic cell cancer vaccine, AST-VAC1, has been selected for an oral presentation at the 2015 American Society of Clinical Onc... |
| | | April 20, 2015 | OncoCyte Announces Initial Data From Ongoing Clinical Study of Collagen Type X as a Marker and Potential Diagnostic for Breast Cancer and Other Types of Human Cancers| Data Presented at American Association for Cancer Research 2015
Annual Meeting
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 20, 2015--
BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation
today announced initial data from a large, prospective clinical study
that showed the potential of PanC-Dx™, OncoCyte’s non-invasive
diagnostic technology based on its proprietary set of cancer markers, as
a non-invasive, blood-based diagnostic test... |
| | | April 09, 2015 | Asterias Biotherapeutics Announces Change to Presentation Time at Needham Healthcare Conference| MENLO PARK, Calif., April 9, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Pedro Lichtinger, President and Chief Executive Officer of Asterias, will present at the 14th Annual Needham Healthcare Conference in New York City on April 15, 2015 at 3:40 PM ET/12:40 PM PT. Mr. Lichtinger's presentation was originally scheduled for 5:00 PM ET/2:00 PM PT.
A live webcast and subs... |
| | | April 06, 2015 | Asterias Biotherapeutics to Present at Needham Healthcare Conference| MENLO PARK, Calif., April 6, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Pedro Lichtinger, President and Chief Executive Officer of Asterias, will present at the 14th Annual Needham Healthcare Conference in New York City on April 15, 2015 at 5:00 PM ET/2:00 PM PT.
A live webcast and subsequent archived replay of the presentation will be accessible at http://asteriasbio... |
| | | March 31, 2015 | LifeMap Solutions and Mount Sinai – National Jewish Health Respiratory Institute Launch Pilot Program of COPD Navigator App| App for Patients is First Component of Broader Chronic-Condition
Platform that Integrates with “Smart” Inhaler Technology and Clinician
Dashboard
SAN JOSE, Calif.--(BUSINESS WIRE)--Mar. 31, 2015--
LifeMap Solutions, an emerging digital therapeutics provider and
subsidiary of BioTime, Inc. (NYSE MKT: BTX), today launched a pilot
program for COPD Navigator, an Apple HealthKit-compliant iOS app that
helps patients monitor and manage the symptoms ... |
| | | March 20, 2015 | OncoCyte Announces Availability of Abstracts With New Clinical Data From Studies of PanC-Dx™ Cancer Diagnostic in Bladder and Breast Cancer| Data to be Presented at American Association for Cancer Research 2015
Annual Meeting
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 20, 2015--
BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation
today announced the online availability of abstracts providing human
clinical data highlighting the potential of PanC-Dx™, OncoCyte’s
class of non-invasive cancer diagnostics based on OncoCyte’s proprietary
set of cancer markers. These markers... |
| | | March 18, 2015 | Asterias Biotherapeutics to Present at Regen Med Investor Day 2015| MENLO PARK, Calif., March 18, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Pedro Lichtinger, President and Chief Executive Officer of Asterias, will present at the Regen Med Investor Day 2015 Conference at the Metropolitan Club in New York City on March 25, 2015 at 5:05 PM ET/2:05 PM PT.
A live webcast and subsequent archived replay of the presentation will be accessibl... |
| | | March 10, 2015 | Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2014 Financial and Operating Results| AST-OPC1 Phase 1/2a Trial in Spinal Cord Injury Initiated in March
Conference Call and Webcast Today, March 10, at 4:30 p.m. ET
MENLO PARK, Calif., March 10, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today reported financial results and progress for the quarter and year ended December 31, 2014, as well as, recent corporate developments.
"Asterias has two therapeutic programs with p... |
| | | March 09, 2015 | Icahn School of Medicine at Mount Sinai and LifeMap Solutions Launch Asthma Study for iPhone| First-of-its-kind asthma study developed using ResearchKit framework
NEW YORK--(BUSINESS WIRE)--Mar. 9, 2015--
The Icahn School of Medicine at Mount Sinai and LifeMap Solutions, a
subsidiary of BioTime (NYSE MKT:BTX), today announced the launch of a
large-scale medical research study that uses the new ResearchKit
framework developed by Apple to make it easy for individuals who
suffer from asthma to participate in studies right from their iPhone.
... |
| | | March 05, 2015 | Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury| MENLO PARK, Calif., March 5, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, announced today that Atlanta-based Shepherd Center, one of the nation's top rehabilitation hospitals for spinal cord injury and brain injury, has commenced enrollment for the Phase 1/2a clinical trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal ... |
| | | March 04, 2015 | /C O R R E C T I O N -- Asterias Biotherapeutics, Inc./| In the news release, Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange, issued today by Asterias Biotherapeutics, Inc. over PR Newswire, we are advised by the company that the second paragraph, third sentence, should read "Of our two lead product candidates, AST-OPC1 for the treatment of complete cervical spinal cord injury has been cleared for a Phase 1/2a clinical trial and AST-VAC2 is expected to enter a Phase 1/2a clinical trial in lung cancer, and we are focused on ex... |
| | | March 04, 2015 | Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange| MENLO PARK, Calif., March 4, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Pedro Lichtinger, President and Chief Executive Officer, will ring The Opening Bell® of the New York Stock Exchange (NYSE) tomorrow, Thursday, March 5, 2015. Asterias began trading as an NYSE MKT listed company on October 8, 2014.
"New York Stock Exchange is a trusted partner to Asterias Biothera... |
| | | March 02, 2015 | Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015| MENLO PARK, Calif., March 2, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that it will release fourth quarter and full year 2014 financial and operating results on Tuesday, March 10, 2015 after the close of the U.S. financial markets. The Company will host a conference call and webcast on Tuesday, March 10, 2015 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the results an... |
| | | February 25, 2015 | LifeMap Sciences Partners with Toldot Genetics to Support Next Generation Sequencing Variant Analysis Commercialization| LifeMap expands its next generation sequencing data analysis business, enhances Toldot’s next generation sequencing analysis services with LifeMap’s integrated knowledgebase and tools
ALAMEDA, Calif., February 25, 2015 ― LifeMap Sciences, Inc. (LifeMap), a subsidiary of BioTime, Inc., announced today a commercial partnership agreement with Toldot Genetics, LTD (Toldot), a subsidiary of BATM Advanced Communications, Ltd. LifeMap’s GeneCards Suite, comprised of the company’s integrated bio... |
| | | February 19, 2015 | LifeMap Sciences Launches GeneAnalytics™ 1.1 with Improved Next Generation Sequencing Data Analysis Features| ALAMEDA, Calif., February 19, 2015 – LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today the release of GeneAnalytics™ v1.1, a powerful and easy-to-use gene set analysis tool that rapidly contextualizes RNAseq and microarray-derived gene expression patterns and function signatures. The tool leverages LifeMap Sciences’ comprehensive integrated biomedical knowledgebase, comprised of GeneCards®, MalaCards, andLifeMap Discovery®, to helpresearchers identify diseases, biologic... |
| | | February 10, 2015 | Asterias Biotherapeutics Completes Public Offering and Private Placement of Common Stock| MENLO PARK, Calif., Feb. 10, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the "Company"), a leading biotechnology company in the emerging field of regenerative medicine, announced today that it has completed the previously announced underwritten public offering and concurrent private placement of its common stock.
The Company raised $5.5 million in aggregate gross proceeds from the public offering and the private placement, which it intends to use for the continued d... |
| | | February 06, 2015 | OncoCyte to Present Cancer Diagnostic Clinical Study Data at AACR Annual Meeting| - BioTime subsidiary’s data collected from prospective
clinical studies in bladder and breast cancer -
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 6, 2015--
BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation
today announced that two abstracts, summarizing clinical studies of
OncoCyte’s PanC-Dx™ diagnostic products for bladder and breast
cancer, have been accepted for poster presentation at the American
Association for Canc... |
| | | February 05, 2015 | Asterias Biotherapeutics Prices Public Offering of Common Stock| MENLO PARK, Calif., Feb. 5, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the "Company"), a leading biotechnology company in the emerging field of regenerative medicine, today announced today that it has priced an underwritten public offering of its common stock at a price of $3.90 per share. Concurrently, the Company entered into a private placement for the sale of common stock at the same price as the underwritten public offering.
Gross proceeds to the Company from t... |
| | | February 04, 2015 | Asterias Biotherapeutics Announces Public Offering of Common Stock| MENLO PARK, Calif., Feb. 4, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST) (the "Company"), a leading biotechnology company in the emerging field of regenerative medicine, today announced that it has commenced an underwritten public offering of its common stock. MLV & Co. LLC is acting as the Sole Book-Running Manager for the offering.
The offering will be made pursuant to the Company's existing effective shelf registration statement, previously filed with the Secu... |
| | | February 04, 2015 | LifeMap Sciences Announces Partnership with Advaita and Commercial Availability of Advaita’s iPathwayGuide in GeneCards®| Advanced pathway analysis tool offered to LifeMap’s GeneCards’ users in more than 3,000 institutions in academia, research hospitals, and leading biopharma companies
ALAMEDA, Calif., February 4, 2015 - LifeMap Sciences, Inc. (“LifeMap”), a subsidiary of BioTime, Inc., announced today a partnership agreement with Advaita Corporation, which develops and sells iPathwayGuide, an advanced web-based pathway analysis platform capable of identifying mechanisms of action and potential drug targets ... |
| | | January 15, 2015 | LifeMap Sciences, a Subsidiary of BioTime, Announces Release of VarElect, the Next Generation Sequencing Phenotyper| ALAMEDA, Calif., January 15, 2015 – LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today the commercial release of VarElect, a powerful, yet easy-to-use application for prioritizing gene variants resulting from next generation sequencing (“NGS”) experiments. VarElect rapidly prioritizes gene variants according to their potential association to a disease or phenotype of interest, and can aid in identifying the roles of genes and their variants in biological processes, heal... |
| | | January 12, 2015 | BioTime Subsidiary OncoCyte Corporation Appoints William Annett to Its Board of Directors| ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 12, 2015--
BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation
today announced that William Annett has been appointed to OncoCyte’s
Board of Directors. Mr. Annett has extensive experience within the
biotechnology and diagnostics industry, having held the position of
Chief Executive Officer at six organizations as well as having
experience in senior management positions at Genentech, Accenture and
... |
| | | January 07, 2015 | Asterias Biotherapeutics to Present at Biotech Showcase™ 2015| MENLO PARK, Calif., Jan. 7, 2015 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that Katharine Spink, PhD, the Company's Chief Operating Officer, will present at the Biotech Showcase™ 2015 Conference in San Francisco on January 12, 2014 at 10:00 AM PT/1:00 PM ET.
A live webcast and subsequent archived replay of the presentation will be accessible at http://asteriasbiotherapeutics.c... |
| |
|
